Compare Lupin with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs TORRENT PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN TORRENT PHARMA LUPIN/
TORRENT PHARMA
 
P/E (TTM) x 40.0 34.4 116.3% View Chart
P/BV x 3.7 8.7 42.2% View Chart
Dividend Yield % 0.6 0.7 84.2%  

Financials

 LUPIN   TORRENT PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-20
TORRENT PHARMA
Mar-19
LUPIN/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8821,964 44.9%   
Low Rs5051,245 40.6%   
Sales per share (Unadj.) Rs339.4453.4 74.9%  
Earnings per share (Unadj.) Rs-5.925.8 -23.1%  
Cash flow per share (Unadj.) Rs15.562.3 24.8%  
Dividends per share (Unadj.) Rs6.0017.00 35.3%  
Dividend yield (eoy) %0.91.1 81.6%  
Book value per share (Unadj.) Rs276.7279.2 99.1%  
Shares outstanding (eoy) m453.00169.22 267.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.03.5 57.8%   
Avg P/E ratio x-116.662.2 -187.4%  
P/CF ratio (eoy) x44.825.8 174.0%  
Price / Book Value ratio x2.55.7 43.6%  
Dividend payout %-100.965.9 -153.0%   
Avg Mkt Cap Rs m314,201271,513 115.7%   
No. of employees `00018.313.6 134.6%   
Total wages/salary Rs m29,86814,038 212.8%   
Avg. sales/employee Rs Th8,400.65,642.6 148.9%   
Avg. wages/employee Rs Th1,632.01,032.4 158.1%   
Avg. net profit/employee Rs Th-147.2320.9 -45.9%   
INCOME DATA
Net Sales Rs m153,74876,728 200.4%  
Other income Rs m4,838571 848.0%   
Total revenues Rs m158,58577,299 205.2%   
Gross profit Rs m24,84919,831 125.3%  
Depreciation Rs m9,7026,177 157.1%   
Interest Rs m3,6305,038 72.1%   
Profit before tax Rs m16,3559,187 178.0%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,521-3,570 210.7%   
Tax Rs m11,5711,254 923.1%   
Profit after tax Rs m-2,6944,363 -61.7%  
Gross profit margin %16.225.8 62.5%  
Effective tax rate %70.813.6 518.5%   
Net profit margin %-1.85.7 -30.8%  
BALANCE SHEET DATA
Current assets Rs m154,13250,375 306.0%   
Current liabilities Rs m92,25251,653 178.6%   
Net working cap to sales %40.2-1.7 -2,416.8%  
Current ratio x1.71.0 171.3%  
Inventory Days Days8292 89.1%  
Debtors Days Days12968 189.3%  
Net fixed assets Rs m89,08283,648 106.5%   
Share capital Rs m906846 107.1%   
"Free" reserves Rs m124,46146,397 268.3%   
Net worth Rs m125,36747,244 265.4%   
Long term debt Rs m17,93339,129 45.8%   
Total assets Rs m249,839141,209 176.9%  
Interest coverage x5.52.8 195.0%   
Debt to equity ratio x0.10.8 17.3%  
Sales to assets ratio x0.60.5 113.3%   
Return on assets %0.46.7 5.6%  
Return on equity %-2.19.2 -23.3%  
Return on capital %8.712.3 70.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45022,103 232.8%   
Fx outflow Rs m19,4705,522 352.6%   
Net fx Rs m31,98016,581 192.9%   
CASH FLOW
From Operations Rs m14,68817,981 81.7%  
From Investments Rs m11,070-2,413 -458.8%  
From Financial Activity Rs m-8,906-13,145 67.8%  
Net Cashflow Rs m16,8532,380 708.0%  

Share Holding

Indian Promoters % 46.6 71.5 65.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 7.0 161.0%  
FIIs % 31.9 12.6 253.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 8.8 114.8%  
Shareholders   98,259 26,511 370.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   FDC  UNICHEM LAB  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  ALEMBIC  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Feb 26, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS